Plain-English translation of NCT05292794 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Parkinson Disease research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study tests CereGate, a new software therapy designed to reduce freezing of gait—those moments when your feet feel suddenly stuck and won't move—in people with Parkinson's disease who already have a deep brain stimulation device implanted in their brain. Researchers want to see whether using this software can help you walk more smoothly and reduce these freezing episodes. The study will track how the treatment affects your walking and gait over about 3 months.
Freezing of gait is a serious problem for many people with advanced Parkinson's disease, even when they're on medication and using deep brain stimulation. This new software therapy offers a potential way to reduce these disabling episodes and improve quality of life without additional surgery or major medication changes.
You likely qualify if…
You likely don't qualify if…
You will visit the study site 5 times over about 3 months: two initial screening visits, one visit to start the software therapy, and two follow-up visits around days 60 and 61. At these visits, you'll be assessed for walking ability and freezing episodes, and you'll use the CereGate software on demand during the 60-day treatment period at home. The study team will monitor how the treatment is working and watch for any side effects or concerns.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States